- Home
- GNTA vs GANX Comparison
GNTA vs GANX Comparison
Compare GNTA & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- GANX
- Stock Information
- Founded
- GNTA 2014
- GANX 2017
- Country
- GNTA Italy
- GANX United States
- Employees
- GNTA N/A
- GANX N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- GANX Health Care
- Exchange
- GNTA Nasdaq
- GANX Nasdaq
- Market Cap
- GNTA 70.8M
- GANX 57.9M
- IPO Year
- GNTA 2021
- GANX 2021
- Fundamental
- Price
- GNTA $4.49
- GANX $1.93
- Analyst Decision
- GNTA Strong Buy
- GANX Strong Buy
- Analyst Count
- GNTA 1
- GANX 5
- Target Price
- GNTA $25.00
- GANX $8.20
- AVG Volume (30 Days)
- GNTA 2.7K
- GANX 226.2K
- Earning Date
- GNTA 01-01-0001
- GANX 05-14-2025
- Dividend Yield
- GNTA N/A
- GANX N/A
- EPS Growth
- GNTA N/A
- GANX N/A
- EPS
- GNTA N/A
- GANX N/A
- Revenue
- GNTA N/A
- GANX N/A
- Revenue This Year
- GNTA N/A
- GANX N/A
- Revenue Next Year
- GNTA N/A
- GANX N/A
- P/E Ratio
- GNTA N/A
- GANX N/A
- Revenue Growth
- GNTA N/A
- GANX N/A
- 52 Week Low
- GNTA $2.79
- GANX $0.89
- 52 Week High
- GNTA $7.28
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- GNTA 59.43
- GANX 53.25
- Support Level
- GNTA $4.25
- GANX $1.80
- Resistance Level
- GNTA $5.98
- GANX $1.85
- Average True Range (ATR)
- GNTA 0.25
- GANX 0.13
- MACD
- GNTA 0.01
- GANX -0.00
- Stochastic Oscillator
- GNTA 19.02
- GANX 60.00
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.